Medicinal Mushrooms Booming, Pure Extract Technologies Inc. First-Mover Strategy Catalyzing Growth

  • Research indicates that functional and medicinal mushrooms offer range of physical and mental benefits
  • Pure Extracts’ milestone-based strategy catalyzing Company growth
  • Strategy includes license procurement, production, marketing of in-house and white label products

Mainstream science is now catching up with what traditional medicine has known for years — that functional and medicinal mushrooms can help treat disease, improve mental cognition and fire up digestion. Pure Extract Technologies Inc., a soon-to-be public, plant-based Canadian extraction company, is on track to position itself as an industry leader through a strategy based on three growth-focused milestones that include the application to Health Canada for a Natural Health Products site license, production and product marketing.

Interest in functional and medicinal mushrooms has skyrocketed in recent years – particularly for medicinal varieties such as psilocybin currently being studied as a treatment option for depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease and addiction (https://ibn.fm/Hl5tn). FDA status on the use of psychedelics appears to be promising, especially since medicinal mushrooms were granted breakthrough therapy status for treatment-resistant depression in 2020 with approvals expected in 2021  (https://ibn.fm/XNMns).

Pure Extracts is positioned to benefit from the growing market for functional and medicinal mushrooms and has already progressed significantly towards becoming an industry leader through its milestone-based strategy. The first phase involved completing the expansion of the Company’s 10,000 sq. ft., state-of-the-art processing facility earlier this year, followed by the submission of an evidence package to Health Canada seeking a Standard Processing Licence.

Having recently received its Standard Processing License from Health Canada, the Company is currently commencing operations and sales for extraction tolling services and white-label products. The third milestone includes full production, compliance testing, submission of private label products to Health Canada and secure distribution with provincial governments. This last milestone involves the activation of sales and marketing campaigns for the Company’s nationally-recognized product lines.

Along with functional and medicinal mushrooms, Pure Extracts is also successfully engaged in the hemp industry through three additional verticals that include marketing for in-house brands, conversion of raw hemp into marketable products and providing white labeling services for existing brands. The Company’s activities are supported by an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. — company that provides third-party clinical trial services through its Good Manufacturing Practice (“GMP”) manufacturing and testing facility that is fully compliant and licensed by Health Canada.

Pure Extracts is leveraging the current transitory state of the functional mushroom market, considered by some analysts to still be in its early stages where dry biomass is still being converted to extracts. The Company’s milestone-based strategy will ensure it grows and moves forward as a leader as it strives to produce consistent, pure mushroom extracts while acceptance of mushrooms wellness products by the mainstream public continues to grow.

For more information, visit the Company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts are available in the company’s newsroom at http://ibn.fm/Pure

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050